ESMO 24: CDK2 Inhibitors - Where Next For The Novel Class?

The Barcelona meeting saw early data from two candidates from Incyte and Pfizer which suggest some progress for a new drug mechanism that has so far underwhelmed.    

Sagrada Familia, Barcelona
• Source: Shutterstock

Early development of CDK2 inhibitors has been beset with tolerability problems, particularly ocular and hematological, but new data for two products suggest that headway is being made for some candidates at least.

The data presented at the European Society for Medical Oncology meeting in Barcelona, Spain, concerned two of the frontrunners: a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from ESMO

More from Conferences